Multimedia

RHEUM ADVISOR ON AIR

Rarest of Them All: Ultra-Rare Rheumatic Diseases – Part 1

February 26, 2021

Rheuminating About COVID-19: A Rheumatologist’s Perspective

February 12, 2021

Uncomplicating the Complicated: Pregnancies in Lupus and APS

January 29, 2021

YEAR IN REVIEW DIGITAL ISSUE

Rheumatoid Arthritis 2018 Year in Review

Rheumatoid Arthritis 2018 Year in Review

VIDEOS

Christopher T. Ritchlin, MD, MPH

Sustained Joint and Skin Improvement Found With Bimekizumab in Psoriatic Arthritis

Christopher T. Ritchlin, MD, MPH, discusses updated bimekizumab data from the BE-ACTIVE trial.

Yusuf Yazici, MD

Novel, Intra-articular Wnt Pathway Inhibitor May Improve Knee Osteoarthritis

Yusuf Yazici, MD, discusses results from a trial evaluating a small molecule inhibitor of the Wnt pathway for the treatment of knee osteoarthritis.

Terence Rooney, MD

Updated Baricitinib Safety Data Available for Active Rheumatoid Arthritis

Terence Rooney, MD, senior medical director, Lilly Bio-Medicines, discusses updated baricitinib safety data presented at ACR/ARHP 2018.

Dr Megan Clowse discusses pregnancy concerns in women with arthritis.

Pregnancy in Inflammatory Arthritis: What Your Patients Need to Know

Megan Clowse, MD, MPH, discusses 2 studies that examine reproductive health concerns in women with inflammatory rheumatic diseases.

Dr Allan Gibofsky speaks at ACR 2017 about inibiting the Wnt pathway for the treatment of OA.

Inhibition of the Wnt Pathway: Potential Benefits for Osteoarthritis

Allan Gibofsky, MD, discusses inhibition of the Wnt pathway and its potential benefits for the treatment of osteoarthritis.

SLIDESHOWS

Uncommon Mimickers of Systemic Lupus Erythematosus

Patients with RA experience localized and generalized bone loss.2 Data have also shown that patients with well-controlled RA have significantly more bone loss than healthy individuals.4 The pathology of bone loss in RA is multifactorial and complex. The pannus, a proliferation of inflamed synovial tissue, releases several proinflammatory cytokines. Some, such as TNF-α, IL-1, IL-6, and IL-17, are osteoclastogenic and promote bone resorption, partly through upregulation of nuclear factor-kB ligand.1,3,5 They also inhibit anti-osteoclastogenic cytokines.1 Further, TNF-α upregulates proteins that inhibit the Wnt pathway, thus suppressing osteoblast activity.1,3,5 The resulting imbalance in bone remodeling, favoring bone resorption, causes bone loss and inferior bone quality. Immobility and glucocorticoid use, both common in patients with RA, also promote bone loss.1,2 Standard risk factors for bone loss may exacerbate RA-induced bone loss.5

Skeletal Complications in Rheumatoid Arthritis: A Comprehensive Review

Artificial intelligence (AI) may be the key to combating burnout among clinicians. According to a report published in Medical Economics, AI can reduce clinicians’ burdens by recognizing patterns in large amounts of data.4 The Cleveland Clinic notes that “with AI’s continued integration into healthcare, caring for patients has become a matter of working smarter, not harder.”3 Considering burnout and depression often develop in tandem, this is especially welcome news for the medical community.

Predictions in Medicine 2019: What’s Ahead

Derm Dx: Erythematous Rash on the Upper Back

Ischemic stroke is the most common severe neurologic complication of APS. Among 1000 people with APS participating in the Euro-Phospholipid Project, 20% presented with stroke and 11% presented with transient ischemic stroke.2,5 About 13% of patients with stroke are aPL-positive,2 and they are more likely to be younger or female compared with aPL-negative patients.3 More than 20% of strokes in patients <45 years may be related to APS.3 In APS, stroke occurs when a clot forms in an arterial vessel of the brain or when clot or plaque debris travels from another site (usually the heart) to a blood vessel in the brain.2,3 Less common cerebrovascular diseases seen in patients with APS that may increase stroke risk are cerebral venous thrombosis, reversible cerebral vasoconstriction syndrome, acute ischemic encephalopathy (a rare feature of SLE), and Sneddon syndrome.3 To reduce stroke risk, clinicians may want to discuss modifiable risk factors for vascular disease, such as smoking and obesity, with those who are positive for aPL.3 Image Credit: Zephyr/Science Source

Examining the Spectrum of Neurologic Manifestations in Antiphospholipid Syndrome

CLINICAL QUIZZES

Muscle Weakness in a Woman With Lupus Nephritis

Lupus Nephritis: A Clinical Knowledge Assessment

Rheumatoid Arthritis Knowledge Assessment

Psoriatic Arthritis: A Clinical Practice Assessment

Rheumatoid Arthritis Assessment and Management: Clinical Quiz

Next post in Rheum Advisor on Air

Rheuminating About COVID-19: A Rheumatologist’s Perspective